BI-765179

This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of Part 1 of this study is to find the highest dose of a medicine called BI 765179 that people with solid tumors can tolerate when taken alone or together with a medicine called ezabenlimab. The goal of Part 2 is to find out whether BI 765179 in combination with a medicine called pembrolizumab helps people with advanced head and neck cancer.
In Part 1, each participant is put into 1 of 2 groups. Participants get BI 765179 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. In Part 2, participants are also divided into 2 groups. 1 group gets a low dose of BI 765179 in combination with pembrolizumab and the other group gets a high dose of BI 765179 in combination with pembrolizumab. Participants receive the study treatment as infusions into a vein.
BI 765179, ezabenlimab, and pembrolizumab are antibodies that may help the immune system fight cancer. In this study, BI 765179 is given to people for the first time.
Participants can stay in the study up to 3 years (Part 1) or 2 years (Part 2) if they benefit from treatment and can tolerate it. The doctors regularly check the participants' health and note any health problems that could have been caused by the study treatment.

Ia期：本试验Ia期部分的主要目的是确定BI 765179单药治疗和与Ezabenlimab联合治疗的最大耐受剂量（MTD），并确定扩展研究的推荐给药剂量（RDE），以便在晚期和/或转移性实体瘤患者中进一步开发联合治疗。 其他目的包括：评估BI 765179的安全性和耐受性；表征药代动力学和药效学特征；以及评估初步临床活性信号。 Ib期：本试验Ib期部分的主要目的是探索在PD-L1表达的转移性或不可治愈的复发性HNSCC患者中评估两种剂量BI 765179与帕博利珠单抗一线联合治疗的初步临床有效性。 其他目的包括：考察不同研究剂量BI 765179与帕博利珠单抗联合治疗的安全性、耐受性、PK和生物标志物；确定首选（优化）剂量用于进一步开发。还将探索患者报告结局指标（PROMs）。